LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that it has signed an exclusive agreement with Bradley Pharmaceuticals, Inc. (NYSE:BDY) for the marketing of Bio-E-Gel® (transdermal estradiol gel) in the United States. Upon execution of the agreement, BioSante received $2.625 million. Additional regulatory and sales based milestone payments could bring the total of such payments from Bradley to BioSante to more than $40 million. In addition, Bradley has agreed to pay to BioSante royalties on sales of Bio-E-Gel, if and when Bio-E-Gel is approved by the U.S. Food and Drug Administration (FDA) and marketed by Bradley.
